Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to characterize a range of brain activation symptoms
associated with depression and response to treatment in midlife men and women with MDD, using
MRI and functional MRI. Moreover, in the female sub-group, the investigators will examine
whether these brain activation symptoms are related to menopausal symptoms (i.e., hot flashes
and night sweats). Also, assessing brain activation before and after the treatment might help
to uncover some mechanisms associated with the pathophysiology of depression and menopause.
Phase:
Phase 3
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
McMaster University St. Joseph's Healthcare Hamilton Wyeth is now a wholly owned subsidiary of Pfizer